Stoke Therapeutics, Inc.
STOK
$11.53
-$0.29-2.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 190.91M | 36.56M | 16.74M | 15.16M | 7.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.91M | 36.56M | 16.74M | 15.16M | 7.85M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 190.91M | 36.56M | 16.74M | 15.16M | 7.85M |
| SG&A Expenses | 53.23M | 48.79M | 46.56M | 44.14M | 41.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 152.67M | 137.93M | 134.05M | 129.69M | 126.30M |
| Operating Income | 38.24M | -101.37M | -117.30M | -114.53M | -118.45M |
| Income Before Tax | 51.55M | -88.98M | -105.46M | -103.57M | -108.53M |
| Income Tax Expenses | 1.28M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.27 | -88.98 | -105.46 | -103.57 | -108.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.27M | -88.98M | -105.46M | -103.57M | -108.53M |
| EBIT | 38.24M | -101.37M | -117.30M | -114.53M | -118.45M |
| EBITDA | 40.33M | -99.19M | -115.03M | -112.16M | -116.02M |
| EPS Basic | 0.84 | -1.68 | -2.10 | -2.19 | -2.42 |
| Normalized Basic EPS | 0.54 | -1.05 | -1.31 | -1.37 | -1.51 |
| EPS Diluted | 0.79 | -1.68 | -2.10 | -2.19 | -2.42 |
| Normalized Diluted EPS | 0.51 | -1.05 | -1.31 | -1.37 | -1.51 |
| Average Basic Shares Outstanding | 227.00M | 215.38M | 203.31M | 191.24M | 179.66M |
| Average Diluted Shares Outstanding | 228.53M | 215.38M | 203.31M | 191.24M | 179.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |